Therapeutic Advances in non-small cell Lung Cancer: Case 1

Credit Area      

Release Date: Dec 1, 2010          Expiration Date: Dec 1, 2011



Program Description


Non-small cell lung cancer (NSCLC) can no longer be considered a homogenous disease. Histologic and molecular features of NSCLC provide important prognostic information and predict response to targeted therapy; therefore, therapy must be individualized according to these criteria to maximize patient outcomes. Maintenance therapy is being increasingly used in NSCLC instead of the traditional approach of first-line therapy, then waiting for disease progression. The staging system for NSCLC has been revised with respect to disease reclassification, likely impacting treatment approaches. The rapidly evolving treatment paradigm for NSCLC has generated practice gaps surrounding the best approaches to improve patient outcomes.

This series of interactive case activities is designed to increase awareness of histologic and molecular features of prognostic and predictive significance in advanced NSCLC in order to optimize systemic therapy choices in the frontline and maintenance settings and beyond. Participants will be presented with patient case scenarios and management choices. The appropriateness of these management choices will be discussed in the context of the currently available clinical evidence.



Faculty


Corey J. Langer, MD, FACP
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Hematology-Oncology Division
University of Pennsylvania
Philadelphia, PA
Read Biography

Mark A. Socinski, MD
Professor of Medicine
Multidisciplinary Thoracic Oncology Program
Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC
Read Biography



University of Michigan Content Reviewer


Samuel M. Silver, MD, PhD
Professor, Division of Hematology/Oncology
Director, University of Michigan Cancer Center
Ann Arbor, MI



Target Audience


These activities were designed to meet the educational needs of medical oncologists, surgical oncologists, and radiation oncologists involved in the management of patients with NSCLC.

Educational Objectives


These activities were designed to address the following IOM competencies: provide patient-centered care; work in interdisciplinary teams; employ evidence-based practice

Case 1 – 50-year-old female nonsmoker with mild cough and dyspnea on exertion [you are here]

At the conclusion of this activity, participants should be able to:

  • Identify biomarkers useful in the workup of treatment-naive patients with advanced NSCLC
  • Select individualized frontline therapy for advanced NSCLC based on tumor histology and molecular features, as well as patient characteristics
  • Indicate the approach to manage toxicities associated with EGFR targeted therapies

 

Case 2 – 65-year-old male former smoker with hip pain, fatigue, mild dyspnea, and hemoptysis [View Case 2]

At the conclusion of this activity, participants should be able to:

  • Select individualized frontline therapy for advanced NSCLC based on tumor histology and molecular features, as well as patient characteristics
  • Identify appropriate continuation or switch maintenance therapy approaches for patients responding to frontline therapy

 

Case 3 – 55-year-old Caucasian male presents with dyspnea on exertion and hemoptysis [View Case 3]

At the conclusion of this activity, participants should be able to:

  • Recognize salient changes in the M classification of non-small cell lung cancer (NSCLC) incorporated into the updated AJCC staging system
  • Indicate the clinical outcomes of patients with advanced squamous cell NSCLC in pivotal clinical trials
  • Select optimal treatment sequence (frontline, maintenance, and beyond) for patients with advanced squamous NSCLC

 

Case 4 – 47-year-old Caucasian female remote prior smoker presents with dyspnea on exertion and rib pain [View Case 4]

At the conclusion of this activity, participants should be able to:

  • Indicate the clinical outcomes of patients with advanced non-squamous cell non-small cell lung cancer (NSCLC) in pivotal clinical trials
  • Select optimal treatment sequence (frontline, maintenance and beyond) for patients with advanced non-squamous NSCLC


Accreditation


The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement


The University of Michigan Medical School designates each educational activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should only claim online credit commensurate with the extent of their participation in the activity.

Disclosure Policy


University of Michigan Medical School (UMMS) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by UMMS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests.

Mark A. Socinski, MD: Speaker's Bureau: Genentech, Eli Lilly; Grant/Research Support: Genentech, Eli Lilly, Pfizer, Abraxis, Celgene

Corey J. Langer, MD, FACP: Speaker's Bureau: Eli Lilly, Genentech, OSI, Bristol-Myers Squibb, ImClone; Grant/Research Support: Bristol-Myers Squibb, Pfizer, Eli Lilly, ImClone, Genentech, OSI; Scientific Advisor: Bristol-Myers Squibb, Eli Lilly, ImClone, Sanofi-Aventis, Pfizer, Amgen, AstraZeneca, Novartis, Genentech, Bayer/Onyx, Abraxis, Abbott, Morphotek, Biodesix, Clarient, Caris Dx

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

UMMS – Samuel M. Silver, MD, PhD; Rockpointe – Paul Walden, PhD; Betsy Dennison, MS, RN, FNP; Jay Katz; Blair St. Amand: Nothing to disclose



FDA Disclosure


The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

System Requirements


Flash Player 7 or later recommended), and one of the following browsers:

  • Windows: Internet Explorer 6 and later, Firefox 1.x and later, Safari 3 and later, Google Chrome, Opera 9.5 and later
  • Macintosh: Safari 3 and later, Firefox 1.x and later, Google Chrome
  • Linux: Firefox 1.x and later


Instructions for Participants and How to Obtain CME Credit


Instructions for Participation and Credit
This activity is a self-study program: Completion of this activity involves successfully completing the case study and accompanying questions and completing the evaluation online at the end of the program, which may take up to 15 minutes.

There is no fee for this program.


By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.


Sponsored By






Supported By


This activity is supported by educational grants from Genentech BioOncology, OSI Oncology, and Lilly USA, LLC. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.